Vericel Stock Forecast, Price & News

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vericel in the last twelve months. There are currently 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Vericel stock.
View analyst ratings for Vericel or view top-rated stocks.

Wall Street analysts have given Vericel a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Vericel wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Vericel is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for Vericel.

Vericel Co. (NASDAQ:VCEL) announced its quarterly earnings data on Tuesday, May, 4th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by $0.03. The biotechnology company earned $34.57 million during the quarter, compared to analyst estimates of $32.04 million. Vericel had a trailing twelve-month return on equity of 3.45% and a net margin of 3.24%. Vericel's revenue for the quarter was up 29.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.10) EPS.
View Vericel's earnings history.

Vericel's stock was trading at $12.08 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, VCEL shares have increased by 376.7% and is now trading at $57.58.
View which stocks have been most impacted by COVID-19.

Vericel updated its FY 2021 earnings guidance on Wednesday, May, 26th. The company provided EPS guidance of - for the period. The company issued revenue guidance of $165 million-$168 million, compared to the consensus revenue estimate of $162.53 million.

8 brokers have issued 1 year target prices for Vericel's shares. Their forecasts range from $31.00 to $65.00. On average, they anticipate Vericel's stock price to reach $49.71 in the next twelve months. This suggests that the stock has a possible downside of 13.7%.
View analysts' price targets for Vericel or view top-rated stocks among Wall Street analysts.

6 employees have rated Vericel CEO Nick Colangelo on Glassdoor.com. Nick Colangelo has an approval rating of 49% among Vericel's employees. This puts Nick Colangelo in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Vericel include Repligen (RGEN), CRISPR Therapeutics (CRSP), Neurocrine Biosciences (NBIX), Denali Therapeutics (DNLI), Fate Therapeutics (FATE), Acceleron Pharma (XLRN), Exelixis (EXEL), Halozyme Therapeutics (HALO), Vir Biotechnology (VIR), Twist Bioscience (TWST), Beam Therapeutics (BEAM), Adaptive Biotechnologies (ADPT), Recursion Pharmaceuticals (RXRX), Sana Biotechnology (SANA) and Kodiak Sciences (KOD).
View all of VCEL's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Vericel investors own include Exelixis (EXEL), Novavax (NVAX), Momo (MOMO), Dynavax Technologies (DVAX), Synergy Pharmaceuticals (SGYP), Sorrento Therapeutics (SRNE), TG Therapeutics (TGTX), Verastem (VSTM), Amarin (AMRN) and NVIDIA (NVDA).

Vericel trades on the NASDAQ under the ticker symbol "VCEL."

Vericel's stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (15.75%), Brown Capital Management LLC (9.86%), Fred Alger Management LLC (5.88%), Waddell & Reed Financial Inc. (5.80%), Federated Hermes Inc. (3.32%) and Artisan Partners Limited Partnership (2.07%). Company insiders that own Vericel stock include Dominick Colangelo, Gerard J Michel, Jonathan Mark Hopper, Michael Halpin, Paul K Wotton and Robert L Md Zerbe.
View institutional ownership trends for Vericel.

VCEL stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG, Kopp Family Office LLC, BNP PARIBAS ASSET MANAGEMENT Holding S.A., Goldman Sachs Group Inc., Pura Vida Investments LLC, Fort Washington Investment Advisors Inc. OH, Parkman Healthcare Partners LLC, and GW&K Investment Management LLC. Company insiders that have sold Vericel company stock in the last year include Dominick Colangelo, Jonathan Mark Hopper, Michael Halpin, Paul K Wotton, and Robert L Md Zerbe.
View insider buying and selling activity for Vericel or view top insider-selling stocks.

VCEL stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Fred Alger Management LLC, Brown Capital Management LLC, Artisan Partners Limited Partnership, Principal Financial Group Inc., Principal Financial Group Inc., Fisher Asset Management LLC, and Bank of New York Mellon Corp.
View insider buying and selling activity for Vericel or or view top insider-buying stocks.

Shares of VCEL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of VCEL stock can currently be purchased for approximately $57.58.

Vericel has a market capitalization of $2.67 billion and generates $124.18 million in revenue each year. The biotechnology company earns $3.04 million in net income (profit) each year or $0.06 on an earnings per share basis.

Vericel employs 273 workers across the globe.

The official website for Vericel is www.vcel.com.

Vericel is headquartered at 64 SIDNEY STREET, CAMBRIDGE MA, 02139.

Vericel's mailing address is 64 SIDNEY STREET, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at 617-588-5555 or via email at [email protected]